Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRI 2 GOIM biomarker-driven cetuximab-based therapy in metastatic colorectal cancer
2020-003008-15Phase 2Active
- Sponsor
- Gruppo Oncologico dell'Italia Meridionale
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Gruppo Oncologico dell'Italia Meridionale. Primary endpoint: Response Rate per line of therapy. Started Jun 2021; status: active.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2020-003008-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003008-15.